SCM
XERS icon

Stonepine Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Stonepine Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.62M Buy
+280,000
New +$1.86M 0.65% 24

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stonepine Capital Management's XERS Position: Q1 2026 in Review

Stonepine Capital Management opened a new position in Xeris Biopharma Holdings (XERS) in Q1 2026: 40,030 shares worth $232K. The stake represents 0.09% of the portfolio and ranks #69 among its holdings. This is a return to the name: Stonepine Capital Management previously reported a position in XERS as recently as Q2 2025.

Stonepine Capital Management first reported a position in XERS in Q4 2021 and has held it in 14 quarters since. The position peaked at $20.3M in Q1 2022. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Stonepine Capital Management held 40,030 shares of Xeris Biopharma Holdings worth $232K as of Q1 2026.
  • Xeris Biopharma Holdings was a new Stonepine Capital Management position in Q1 2026.
  • Xeris Biopharma Holdings made up 0.09% of Stonepine Capital Management's portfolio in Q1 2026, its #69 holding.
  • Stonepine Capital Management first reported a position in Xeris Biopharma Holdings in Q4 2021 and has held it in 14 quarters since.
  • Stonepine Capital Management's Xeris Biopharma Holdings position peaked at $20.3M in Q1 2022.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.